September 23, 2021  – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil

CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021, ADUHELM™ (aducanumab-avwa) 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration (FDA). We are committed to responding to questions from the Alzheimer’s disease community and providing more details about our plans.

Today, on behalf of my Biogen colleagues, I am incredibly humbled to share that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELMTM (aducanumab-avwa), the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque.  We come

Robert W. Pangia, who has served as a Biogen director since 1997, will retire from the company’s Board this year, effective at the annual meeting of stockholders. Biogen and the Board of Directors would like to thank Bob for his decades-long service and invaluable support.

Following last week’s deeply concerning events in Washington DC, we are suspending all political donations to allow a thorough review of our political contribution criteria and policies. Biogen supports the rule of law and democratic process and calls for a peaceful transition of power.

CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for

In 2020, the cost of Alzheimer’s in the U.S. is estimated to be over $500 billion, impacting countless patient, family and caregiver lives.  If approved, aducanumab may slow clinical decline and potentially help patients maintain independence longer. This could constitute an important breakthrough,

On September 29, 2020, it was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual advisory committee meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to review data supporting the Biologics License Application (BLA)

We are thankful for the service of Lynn Schenk as a director of IDEC since 1995 and then a director of the merged Biogen company since 2004. Lynn will retire from the Biogen Board at the end of her current term, which expires at the 2020 annual meeting of stockholders.

The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world. As governments, businesses and other organizations take unprecedented measures to help mitigate the spread of the outbreak, we want to reinforce our deep commitment to our employees, our